14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today ALDX ranks #16921 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Aldeyra Therapeutics Stock Forecast NASDAQ:ALDX

$3.54 (1.43%)

Volume: 945k

Closed: Jan 19, 2022

Hollow Logo Score: -4.884

Aldeyra Therapeutics Stock Forecast

$3.54 (1.43%)

Volume: 945k

Closed: Jan 19, 2022

Score Hollow Logo -4.884

Aldeyra Therapeutics Company Profile

131 Hartwell Avenue

Lexington MA 02421



Industry: Biotechnology

Sector: Healthcare

Aldeyra Therapeutics


Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for diseases caused by inflammation and inborn errors of metabolism in the United States and internationally. It is developing NS2, a small molecule designed to trap and allow for the degradation of aldehydes. Its product is used for the treatment of allergic conjunctivitis, noninfectious anterior uveitis, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is based in Lexington, Massachusetts.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE